Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels  by Jones, Suzanne et al.
Kidney International, Vol. 59 (2001), pp. 1529–1538
DIALYSIS – TRANSPLANTATION
Bicarbonate/lactate-based peritoneal dialysis solution increases
cancer antigen 125 and decreases hyaluronic acid levels
SUZANNE JONES, CLIFFORD J. HOLMES, RAYMOND T. KREDIET, RUTH MACKENZIE, DIRK FAICT,
ANDERS TRANAEUS, JOHN D. WILLIAMS, GERALD A. COLES, and NICHOLAS TOPLEY,
on behalf of the BICARBONATE/LACTATE STUDY GROUP1
Institute of Nephrology, University of Wales College of Medicine, Cardiff, Wales, United Kingdom; Baxter Healthcare
Corporation, Renal Division, McGaw Park, Illinois, USA; Department of Nephrology, Academisch Medisch Centrum,
Amsterdam, The Netherlands; Baxter Healthcare Europe, Nivelles, and Baxter Healthcare, Renal Europe, Brussels, Belgium
51). In the same group of patients, HA levels were significantlyBicarbonate/lactate peritoneal dialysate increases cancer anti-
decreased at both three and six months in the B/L-treatedgen 125 and decreases hyaluronic acid levels.
group (time 5 0, 336.0 6 195.2; time 5 3 months, 250.6 6Background. In a randomized, controlled trial comparing a
167.6; and time 5 6 months, 290.5 6 224.6 ng/mL; mean 6pH neutral, bicarbonate/lactate (B/L)-buffered PD solution to
SD; P 5 0.006, N 5 47 and P 5 0.003, N 5 48, respectively).conventional acidic, lactate-buffered solution (C), the over-
No significant changes in CA125 or HA levels were observednight dialysate levels of markers of inflammation/wound heal-
in the control group. There were no significant changes ob-ing [hyaluronic acid (HA)], mesothelial cell mass/membrane
served in the levels of PICP or TGF-b1 in the B/L or C groupintegrity [cancer antigen 125 (CA125)], and fibrosis [trans-
over the six-month treatment period.forming growth factor-b1 (TGF-b1) and procollagen I peptides
Conclusions. These results suggest that continuous therapy(PICP)] were assessed over a six-month treatment period.
Methods. One hundred six patients were randomized (2:1) with the B/L solutions modulates the levels of putative markers
to either the B/L group or C group. Overnight effluents were of peritoneal membrane integrity and inflammation. In the
collected at entry into the study (time 5 0 all patients on control long term, this may positively impact the peritoneal membrane,
solution) and then at three and six months after randomization. increasing its life as a dialyzing organ.
Aliquots were filtered, stored frozen, and assayed for HA,
CA125, TGF-b1, and PICP. Differences between groups were
assessed by repeated-measures analysis of variance for unbal-
Peritoneal dialysis (PD) has been successfully em-anced data using the SAS procedure MIXED.
ployed as a form of renal replacement therapy for overResults. In patients treated with B/L, there was a significant
(P 5 0.03) increase in CA125 after six months compared with 20 years. During the last decade, numerous in vitro and
time 5 0 (19.76 6 11.8 vs. 24.4 6 13.8 U/mL; mean 6 SD; N 5 in vivo reports have demonstrated that conventional lac-
tate-buffered PD solution formulations have bioincom-
patible characteristics [1, 2]. These are related to their1 Members of the Bicarbonate/Lactate Study Group are: D. O’Don-
acidity, buffer composition, glucose content, and hyper-oghue (Hope Hospital, Salford, UK), L. Frenken (De Wever Zieken-
huis, Heerlen, Netherlands), E. Brown (Charing Cross Hospital, Lon- osmolality [3–6]. Despite this evidence of its bioincom-
don, UK), J. Walls (Leicester General Hospital, Leicester, UK), F.B. patibility, acidic lactate-buffered PD fluids (PDFs) arePedersen and P. Freese (Odense Universitetshospital, Odense, Den-
still used in the vast majority of PD patients.mark), Olof Heimbu¨rger (Karolinska Instituet, Huddinge Hospital,
Sweden), R. Gokal (Manchester Royal Infirmary, Manchester, UK), One of the major inhibitory pathways by which con-
B. Junor (Western Infirmary, Glasgow, UK), R. Maiorca (Ospedale ventional PD solutions modulate cell function is relatedRegionale “Spedali Civili”), L. Weiss (Central Sjukhuset, Karlstad, Swe-
to the combination of their acidity and lactate concentra-den), K. Farrington (Lister Hospital, Stevenage, UK), J. Kristiensen
(Fredericia Sykehus, Fredericia, Denmark), J. Ahlme´n (Ka¨rnsjukhuset, tion [4, 7]. To address this issue, the introduction of
Sko¨vde, Sweden), D. Struijk (Academisch Medisch Centrum, Amster- bicarbonate, the body’s natural buffering system, whichdam, Netherlands), R. Brouwer (Medisch Spectrum Twente, Enchede,
Netherlands), J.-P. Ryckelynck (CHU Clemenceau, Caen, France), and would allow the creation of a neutral pH solution, was
A.M. Hopwood (Baxter Healthcare, Brussels, Belgium). considered desirable [8]. Its introduction was, however,
initially hampered by the problem of calcium carbonateKey words: dialysate, biocompatibility, effluent markers, peritoneal
membrane integrity. precipitation at the bicarbonate levels required to correct
metabolic acidosis in renal failure [9]. The development
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rated during the sterilization process, thus avoiding pre- throughout the body, capable of inducing extracellular
matrix expansion and collagen deposition [29]. PICP andcipitation of calcium carbonate [10, 11]. In addition, the
glucose compartment is maintained at a pH value during procollagen III N-terminal peptide (PIIICP) have been
used as indirect measures of collagen turnover in varioussterilization and storage, which diminishes the degree of
glucose degradation product formation [12]. Because the tissues, including the peritoneal cavity [26, 30–32].
Our results demonstrate that patients continuously ex-two chambers are mixed immediately prior to use, this
system allows the infusion of a bicarbonate-based solu- posed to B/L-buffered solutions exhibited significantly
elevated effluent levels of CA125 and reduced levels oftion at neutral pH with reduced levels of glucose degra-
dation products. hyaluronan in their overnight effluent. These observations
suggest reduced proinflammatory potential and im-In vitro studies with bicarbonate-based formulations
have consistently shown improvements in biocompatibil- proved mesothelial cell integrity within the dialyzed peri-
toneum, possibly indicating better preservation of perito-ity parameters over acidic, lactate-based solutions. In addi-
tion, animal infusion models have shown that peritoneal neal homeostasis and the long-term function of the
peritoneal membrane in patients dialyzed with more bio-mesothelial morphology is also better preserved follow-
ing repeated solution infusion [reviewed in 13]. While compatible solutions.
this large body of experimental data provides indirect
evidence for the potentially improved biocompatibility
METHODS
of bicarbonate-buffered solutions, few data are available
Study design and test solutionson their impact on the peritoneum in vivo. Previous
clinical trials with various bicarbonate formulations have This study formed part of a randomized, prospective,
controlled, multicenter study comparing a new 25 mmol/Ldemonstrated that they are well tolerated and clinically
effective [10, 11, 14–17]. bicarbonate/15 mmol/L lactate (B/L) with a standard
40 mmol/L lactate-buffered PD (C) solution over a six-To assess the in vivo impact of different infused solu-
tions on parameters related to peritoneal host defense, month treatment period [33]. For an initial run-in phase
of four weeks, all patients received their standard dialysiswe and others have used an ex vivo approach to measure
peritoneal macrophage (PMØ) function [6, 18]. Using regimen using the conventional PD solution (Dianeal
PD4; 40 mmol/L lactate, pH 5.3 to 5.5 containing 1.36,this type of study, we have recently reported that PMØ
function in patients exposed to pH neutral bicarbonate- 2.27, or 3.86% dextrose as appropriate; Baxter Health-
care, Deerfield, IL, USA). After this run-in period, pa-and particularly bicarbonate/lactate (B/L)-buffered solu-
tions was superior [as assessed by ex vivo tumor necrosis tients were randomized in a 2:1 ratio to either B/L or
control solutions for the trial period. All patients re-factor-a (TNF-a) synthesis] than that seen in cells ex-
posed in vivo to acidic lactate-buffered solutions [19, 20]. ceived their standard dialysis regimen using either C or
B/L containing either 1.36, 2.27, or 3.86% dextrose. TheWhile ex vivo cell function studies provide evidence
for modulation of cellular function in vivo, there is a electrolyte concentrations of each solution were identical
[19]. The study design is shown in Figure 1.growing interest in the measurement of potentially prog-
nostic markers of the structural and functional changes
Patientsthat occur in the peritoneal environment during PD
[21–26]. In this respect, the effluent concentrations of This study took place in 17 centers in Europe [33]. A
total of 106 patients were initially recruited, of which 70markers of mesothelial cell integrity/mass, inflammation,
fibrosis, and angiogenesis have been evaluated in various were randomly allocated to B/L and 36 to the control
group. Each patient gave written informed consent priorgroups of PD patients [21–26].
In the present study, effluent concentrations of cancer to participation, and the local ethics committee for each
center gave approval for the study. Effluent samples wereantigen 125 (CA125), hyaluronic acid (HA), trans-
forming growth factor-b1 (TGF-b1), and procollagen I received from 68 patients in the B/L group and from 35
patients in the control group. The baseline demographicsC-terminal peptide (PICP) were evaluated. CA125 is
used as a marker of ovarian neoplasms but has subse- in the two patients groups were not statistically different
nor was the time on dialysis prior to the commencementquently been suggested as a marker of mesothelial cell
mass/turnover [27]. HA has been suggested as a marker of the study (Table 1). The clinical changes occurring in
the two patient groups are reported elsewhere [33].of inflammation and tissue remodeling in the peritoneal
cavity [21, 28]. In PD patients, HA levels appear to Prior to entry in the study, patients had been on contin-
uous ambulatory PD (CAPD) for at least three monthsincrease with time on PD suggestive of ongoing inflam-
mation, wound healing, or mesothelial cell repair pro- and were treated with a 40 mmol/L lactate dialysis solu-
tion (Dianealt PD4) using an integrated disconnect sys-cesses [21]. TGF-b1 and PICP were selected as potential
markers of fibrosis. TGF-b1 is the prototypical cytokine tem (Twin-bag) for at least one month. They had to have
a normalized (to body surface area) glomerular filtrationassociated with fibrogenesis in many disease processes
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Fig. 1. Flow diagram of patients and sample
collection and measurement during the study.
Table 1. Baseline demographics
Patient group
Lactate Bicarbonate/lactate
Demographic variables N 5 35 N 5 68 P value
Age years 57.4 55.8 0.4711
Range (min-max) 23.6–76.6 26.0–77.3
Body weight kg 75.2 71.6 0.2230
Range (min-max) 52.8–124.0 44.8–103.0
Height cm 169.0 168.8 0.8263
Range (min-max) 153–187 151–186
Males 18 (51.4%) 41 (60.3%) 0.3890
Primary renal disease 0.4093
Glomerulonephritis 8 15
Diabetic nephropathy 3 4
Hypertensive nephropathy 3 12
Polycystic kidney disease 7 5
Interstitial/obstructive 3 8
Other 11 24
Diabetic type 7 7 0.2861
Type 1 2 5
Type 2 5 2
Normalized RRF 2.92 2.83 0.8508
Weekly total Kt/V 2.20 2.26 0.4729
Weekly normalized creatinine clearance L/week/1.73 m2 75.03 76.50 0.6404
Mean time on dialysis at the start of the study 20.15 22.56 0.6863
rate of #7 mL/min/1.73 m2 (nRRF, average of renal and had other serious illnesses, including the need for hospi-
talization in the previous 30 days. Patients were alsocreatinine clearance) and used four or five, 2 to 2.5 L
exchanges a day for seven days a week with no dry excluded if they were known to be HIV positive, were
pregnant or lactating, were adding bicarbonate to theirperiod. Their total weekly creatinine clearance (perito-
neal and renal) had to be $55 L/1.73 m2 body surface bags, or were taking bicarbonate orally.
By six months, 55 patients remained in the treatmentarea, as determined by the PD Adequestt program (ver-
sion 1.4a; Baxter Healthcare). Patients were excluded if group, and 29 remained in the control population. With-
drawals occurred because of transplantation (7 patients,they had an acute or chronic exit site or tunnel infection,
had completed a course of antibiotics for exit site/tunnel 4 controls and 3 B/L), adverse events such as peritonitis
(9 patients: 3 controls, and 6 B/L) and unavailability ofinfection or for peritonitis in the previous 30 days, or
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treatment options (bag size, night exchange) with the creased. This indicated that the data were highly skewed
experimental B/L product (4 patients). and therefore log transformed for analysis. We used log
transformation to normalize the data and stabilize the
Effluent collection variances. As the data were serial over time within pa-
At the end of the four-week run-in phase and prior tients but unbalanced data across patients, we analyzed
to randomization (time 5 0) and at time 5 3 months the data by repeated-measures analysis of variance
and time 5 6 months, peritoneal effluent was collected (ANOVA) for unbalanced data using the SAS procedure
from a timed overnight (18 hours) dwell using a 1.36% MIXED [35–37]. This was performed separately for each
dextrose solution appropriate to the patient’s random- group (C and B/L). A value of P , 0.05 was considered
ization. Approximately 50 mL of overnight (18 hours) statistically significant.
drain fluid were collected, rendered cell free by filtration
(0.4 m filter; Millipore UK, Ltd.) and then aliquoted into
RESULTS5 mL cryovials (Nunc, Life Technologies Ltd., Paisley,
UK) for storage at 2708C prior to assay in a single Significant variability was seen over time for all pa-
laboratory. Actual effluent samples received for analysis tients irrespective of the peritoneal markers in question
from each sampling time period are shown in Figure 1. (Figs. 2–5). There was no correlation between these dif-
Reasons for missing samples were classified into patient ferences and patient group characteristics, such as age
dropout or not collected. or previous time on dialysis, emphasizing the require-
ment to compare the trial phase to run-in, thereby using
Peritoneal effluent markers the individual patients as their own controls.
Transforming growth factor-b1. TGF-b1 was mea-
Cancer antigen 125sured following acid activation of samples by enzyme-
linked immunosorbent assay (ELISA; Amersham-Phar- Repeated-measures ANOVA comparing data from
macia Biotech UK Ltd., Amersham, UK) as per the baseline (time 5 0) and trial phases within each treat-
manufacturer’s instructions. The minimal detectable ment group revealed a significant increase in effluent
concentration in the assay was 4 pg/mL, and the coeffi- CA125 levels after six months continuous treatment with
cient of variation for intra-assay and interassay variabil- B/L (P 5 0.0274; Fig. 2). Median (min-max) CA125
ity was between 3.0 and 4.0% and 7.7 to 13.4%, respec- levels (U/mL) increased from 16.73 (3.36 to 61.5) at
tively. time 5 0 to 17.64 (2.88 to 61.07) at three months (P 5
Procollagen I peptides. PICPs were measured by 0.0931, N 5 53) and 21.23 (5.9 to 63.8) after 6 months
ELISA (Prolagen C assay; Metrabiosystems Inc., Sun- (P 5 0.0274, N 5 51). In the control group, median
nyvale, CA, USA) as per the manufacturer’s instructions. CA125 levels did not change between the run-in and the
The minimum detectable concentration in the assay was trial phases of the study. At time 5 0, three and six
0.2 ng/mL, and the coefficient of variation for intra-assay months CA125 levels (U/mL) were 14.44 (4.3 to 85.2),
and interassay variability was between 5.5 and 6.8% and
14.0 (3.5 to 64.29, P 5 0.707, N 5 31), and 15.9 (1.32 to
5.0 to 7.0%, respectively.
50.85, P 5 0.792, N 5 26), respectively.Hyaluronic acid. HA was measured by commercial
ELISA (Hyaluronic Acid “Chugai” Quantitative test kit; Hyaluronic acid
TCS Biological Ltd., Bucks, UK) according to the manu-
A comparison of HA levels (ng/mL) in timed over-facturer’s instructions. The minimum detectable concen-
night effluent between baseline (time 5 0) and trialtration in the assay was 10 ng/mL and the coefficient of
phases identified a significant reduction in its levels (atvariation for intra-assay and interassay variability was
both 3 and 6 months) in the B/L group (Fig. 3). Medianbetween 3.6 and 4.2% and 5.7 to 7.0%, respectively [34].
(min-max) levels were 305.0 (63.35 to 1095.0) at time 5Cancer antigen 125. CA125 was measured with the
0, which decreased significantly after three months toIMx CA125 microparticle enzyme immunoassay (Abbot
213.15 (11.04 to 757.0, P 5 0.0058, N 5 47) and at sixIMx; Abbot Laboratories, Chicago, IL, USA) as per the
months to 243.2 (55.05 to 1382.2, P 5 0.0033, N 5 48)manufacturer’s instructions.
in those individuals dialyzed with B/L. In the control
Statistical analysis group, HA levels did not change significantly between
the run-in and trial phases of the study. At time 5 0,All effluent samples were archived centrally and then
three- and six-month HA levels (ng/mL) were 278.4shipped for analysis, in a blinded fashion, to Cardiff
(30.05 to 780.5), 238.6 (40.9 to 844.6) (P 5 0.69, N 5or Amsterdam. The data generated were collated, and
30), and 316 (88.25 to 912.14, P 5 0.77, N 5 25), respec-statistical evaluations were performed as described in
tively, for patients continuously treated with acidic lactate-this article. The variability estimates for all parameters
measured increased when the respective means in- buffered solutions.
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Fig. 2. Effect of continuous treatment with
control (PD4, 40 mmol/L lactate, pH 5.2) or
B/L (25 mmol/L bicarbonate/15 mmol/L lac-
tate, pH 7.3) on the changes in effluent cancer
antigen 125 (CA125) levels in overnight timed
dwell effluents. Data are presented as median
(dark line), range (box), and 95% CI (error
bars) after the run-in phase (t 5 0 all patients
treated with control solutions) and the trial
phase [at 3 and 6 months (t 5 3 and t 5 6) in
patients randomized to control or B/L solu-
tions]. N represents the number of patients in
each group. Data comparisons were made
with repeated-measures ANOVA.
Fig. 3. Effect of continuous treatment with
control (PD4, 40 mmol/L lactate, pH 5.2) or
B/L (25 mmol/L bicarbonate/15 mmol/L lac-
tate, pH 7.3) on the changes in effluent hyalur-
onic acid (HA) levels in overnight timed dwell
effluents. Data are presented as median (dark
line), range (box), and 95% CI (error bars)
after the run-in phase (t 5 0 all patients
treated with control solutions) and the trial
phase [at 3 and 6 months (t 5 3 and t 5 6) in
patients randomized to control or B/L solu-
tions]. N represents the number of patients in
each group. Data comparisons were made
with repeated measures ANOVA.
Transforming growth factor-b1 ther group (Fig. 5A). Median (min-max) levels in the
B/L group were ng/mL 286.6 (93.7 to 486.4), 318.2 (106.7Analysis of the TGF-b1 levels in the C and B/L groups
to 504.3, P 5 0.48, N 5 47), and 245.2 (107.5 to 422.85,revealed no statistically significant changes in either
P 5 0.0.14, N 5 50) at time 5 0, time 5 3 months, andgroup (Fig. 4A). Median (min-max) levels in the B/L
time 5 6 months, respectively. In the control group,group were ng/mL 83.21 (23.6 to 464.4), 77.52 (25.87 to
median (min-max) values were 254.9 (107.1 to 699.9),395.7, P 5 0.27, N 5 50), and 88.67 (22.87 to 429.1, P 5
246.88 (59.3 to 860.8, P 5 0.58, N 5 30), and 252.29 (98.90.48, N 5 52) at time 5 0, time 5 3 months, and time 5
to 819.3, P 5 0.76, N 5 24) at time 5 0, time 5 3 months,6 months, respectively. In the control group, median
and time 5 6 months, respectively.(min-max) values were 85.03 (23.6 to 433.0), 85.05 (28.12
to 374.09, P 5 0.69, N 5 30), and 93.06 (27.37 to 474.2,
P 5 0.51, N 5 26) at time 5 0, time 5 3 months, and
DISCUSSIONtime 5 6 months, respectively.
To date, the vast majority of biocompatibility studies
Procollagen I peptides have involved in vitro assessment of cell functional pa-
rameters following various periods of exposure to differ-Analysis of the PICP levels in the control and B/L
groups revealed no statistically significant changes in ei- ent PD solutions [reviewed in 2, 38]. These studies have
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Fig. 4. Effect of continuous treatment with
control (PD4, 40 mmol/L lactate, pH 5.2) or
B/L (25 mmol/L bicarbonate/15 mmol/L lac-
tate, pH 7.3) on the changes in effluent
TGF-b1 levels in overnight timed dwell efflu-
ents. Data are presented as median (dark
line), range (box), and 95% CI (error bars)
after the run-in phase (t 5 0 all patients
treated with Control solutions) and the trial
phase [at 3 and 6 months (t 5 3 and t 5 6) in
patients randomized to control or B/L solu-
tions]. N represents the number of patients in
each group. Data comparisons were made
with repeated-measures ANOVA.
Fig. 5. Effect of continuous treatment with
control (PD4, 40 mmol/L lactate, pH 5.2) or
B/L (25 mmol/L bicarbonate/15 mmol/L lac-
tate, pH 7.3) on the changes in effluent procol-
lagen I peptide (PICP) levels in overnight
timed dwell effluents. Data are presented as
median (dark line), range (box), and 95% CI
(error bars) after the run-in phase (t 5 0 all
patients treated with control solutions) and
the trial phase [at 3 and 6 months (t 5 3 and
t 5 6) in patients randomized to control or
B/L solutions]. N represents the number of
patients in each group. Data comparisons
were made with repeated-measures ANOVA.
identified the potential of solution components to modu- sumed that they play a significant role in this process
(abstract; ibid) [40, 41, 49].late cell behavior; however, they are not able to offer
information on the in vivo response of the peritoneal Insight into the effects of specific solution components
is available from animal studies in which dialysis solu-cavity to conventional or newer dialysis solution compo-
nents during long-term clinical dialysis. The response of tions or their components have been infused repeatedly,
and their effects on peritoneal and mesothelial cell mor-the peritoneum to dialysis in vivo has been observed
directly from peritoneal biopsy samples obtained cross phology have been evaluated [50–53]. In humans, the
majority of data available on the in vivo effect of solutionsectionally from PD patients (abstract; Topley et al, J
Am Soc Nephrol 10:324A, 1999) [39–48]. While these components is derived from ex vivo measurements of
cell function. These experiments usually assess cell func-studies have identified that significant interstitial and
vascular changes occur in the peritoneal membrane (with tion in PMØ isolated from drain effluent after varying
in vivo dwell times [6, 18–20, 54]. To date, the findingstime on PD), they have not as yet identified whether
specific dialysis solution components contribute to the of these studies have largely mirrored in vitro observa-
tions and are suggestive of improvements in function indescribed histologic alterations, although it is widely as-
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cells exposed to potentially more biocompatible solu- of increased CA125 concentrations in this study concur
with previously reported studies in which solutions spe-tions such as those buffered with bicarbonate or B/L
mixtures [13, 19, 20, 55–58]. While these studies appear cifically manufactured to reduce glucose degradation
product (GDP) formation and acidity have a similar im-to indicate the potentially beneficial effects of more bio-
compatible solutions on both peritoneal cell function and pact in vivo (abstract; Simonsen et al, J Am Soc Nephrol
10:322A, 1999) [67]. Interestingly, in the former study,host defense against infection, they do not in themselves
provide any direct information about the status (or switching to the low GDP solution was associated with
increased CA125 levels that were subsequently reducedchanges) of the peritoneal membrane during ongoing
dialysis, and neither can they be used as prognostic mark- when the patients reverted to acidic lactate-buffered so-
lutions. These data indicate that continuous exposure toers of adverse changes occurring over time or in response
to infection during PD. conventional solutions is at least partly responsible for
the generalized decrease of CA125 (and presumablyOver the past decade, interest has increased in the
identification of potential markers that can be measured mesothelial cell mass) over time on PD [23, 67]. While
the reduced GDP levels in the solutions (including thein the available peritoneal drain effluent that might pro-
vide an indication of the overall status of the peritoneum B/L solutions used in the present study [12]) are poten-
tially responsible for the observed changes in CA125in vivo [59, 60]. These markers also might represent
candidate biocompatibility markers, changes in which (and possibly other markers), further direct evidence is
required to substantiate this hypothesis [68, 69]. Reducedbeing indicators of the host’s long-term response to dif-
ferent dialysis solutions (components thereof) or uremia GDP levels in solutions have previously been demon-
strated to have beneficial effects in vitro, and may offerper se [49]. To date, several candidate markers have
been identified based on their relationship to changes in some biocompatibility advantages in vivo compared with
conventional solutions [69, 70].inflammatory status, mesothelial cell integrity, and the
processes of wound healing and fibrosis [21–23, 25–27]. Continuous dialysis with B/L was associated with de-
creases in effluent HA levels after both three and sixIn the present study, we evaluated the impact of con-
tinuous dialysis with a potentially more biocompatible, months of treatment. This glycosaminoglycan polymer
has many described functions, including participation inneutral pH solution formulation buffered with a mixture
of bicarbonate and lactate on changes in these parame- angiogenesis, fibrosis, wound healing, tissue remodeling,
and inflammation [71, 72]. In the peritoneum, HA isters in a large group of CAPD patients [33]. Continuous
dialysis with B/L was associated with significantly ele- produced by both fibroblasts and peritoneal mesothelial
cells [73, 74]. Its synthesis can be stimulated with pro-vated CA125 levels after six months of treatment. This
220 kD glycoprotein, a marker of ovarian neoplasms but inflammatory cytokines such as interleukin (IL)-1b, and
its levels correlate with IL-1 and IL-6 levels, indicatingof unknown function, was first suggested by Visser et al
as a putative marker of mesothelial cell mass/turnover its link to ongoing inflammation [73, 74].
Hyaluronic acid has been suggested as a marker of[27]. These authors were able to demonstrate its constant
secretion by cultured human mesothelial cells, which inflammation and tissue remodeling in the peritoneal
cavity [21, 28]. In PD patients, HA levels appear towas apparently unaffected by known proinflammatory
activators. While this has been disputed by others increase with time on PD, suggestive of ongoing and
increasing inflammation, wound healing, or mesothelial[61, 62], there is a general consensus that despite the
limitations of previous cross-sectional studies [23, 25], cell repair processes [21]. The observations made in this
study of decreasing HA levels with time of therapy paral-its constant secretion rate in vivo and its cell specificity
(only secreted by mesothelium) indicate that longitudi- lel previously reported data and suggest that even follow-
ing relatively short-term exposure to the B/L solution,nal changes in this parameter (in individuals with base-
line historic values) may be a marker of the viability/ decreases in its intraperitoneal levels are observed. This
rapid reduction in HA levels following a change to astatus of the mesothelium [49]. The mesothelium plays
a pivotal role in the peritoneum’s response to inflamma- potentially more biocompatible solution was also ob-
served in our current study (abstract; Simonsen et al, Jtion and tissue injury [63, 64]. During PD, continuous
mesothelial injury occurs, as evidenced by increased Am Soc Nephrol 10:322A, 1999). As HA contributes to
a great number of cellular and inflammatory processesnumbers of exfoliated cells present in dialysis effluent,
and this injury is exacerbated during episodes of peritoni- and many of its actions are molecular weight dependent,
the absolute meaning of decreased intraperitoneal levelstis [44, 65]. A complete loss of mesothelium following
injury, and/or failure of the remesothelialization process, remains to be precisely determined. Previous data dem-
onstrating increasing HA levels with time on PD, how-appears to precede end-stage sclerosis [66]. This suggests
that in addition to its role in peritoneal host defense, the ever, suggest that these increases parallel changes in the
peritoneum (structural/functional) that occur with timemesothelium is important in the maintenance of perito-
neal membrane structure and function. The observations on dialysis (abstract; Topley et al, ibid) [42, 75, 76]. While
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changes in HA may not be directly linked to these pro- also higher in the treatment group. The increased 24-
hour ultrafiltration was not explained by a difference incesses, reductions in its levels suggest a reduction in
the concentration of glucose in the bags used by theintraperitoneal inflammation and a normalization of
patients, as the difference remained when the ultrafiltra-peritoneal homeostasis. In the present study, the maxi-
tion was normalized for mean glucose concentration [33].mal reduction in HA was observed after three months of
The results of the present study indicate that mesothe-treatment. It is not clear, however, whether the apparent
lial cell mass increases and proinflammatory markers(but not statistically significant) increase between three
(HA) decrease in the peritoneal effluent of patients ex-and six months represents a reversion of HA levels to-
posed to B/L-buffered PD compared with those seenward the normal increasing trend seen in conventionally
when exposed to conventional acidic, lactate-buffereddialyzed patients [21]. The patients enrolled in this study,
solutions. These observations complement previous re-however, had all been previously dialyzed with conven-
ports of improved in vitro and ex vivo measurements oftional solutions for in many cases extended periods.
cell function using identical solution formulations [19,Whether this limits the ability of more biocompatible
20, 55]. In evaluating these results, it must also be bornetherapy to reverse the changes previously induced in the
in mind that the patients entering this study had all beenperitoneum by conventional dialysis awaits more ex-
previously dialyzed with acidic lactate-buffered solu-tended clinical trials comparing the impact of more bio-
tions, some for extended time periods. In this context,compatible solutions in both new and previously dialyzed
the data indicate (as in other similar studies) that thepatients.
conversion to a more biocompatible solution is able toTransforming growth factor-b1 and the PICP were
reverse the observed decline in CA125 and increase inselected as potential markers of fibrosis. TGF-b1 is the
HA levels that occur with time on PD [21, 23]. Whileprototypical cytokine associated with fibrogenesis in
these data do not provide definitive clinical proof of themany disease processes throughout the body, capable
long-term benefits of conversion to more biocompatibleof inducing extracellular matrix expansion and collagen
solutions, they do suggest that more biocompatible ther-deposition [29]. PICP and PIIICP have been used as
apy has a potentially positive (and rapid) impact withinindirect measures of collagen turnover in various tissues,
the peritoneal cavity. Whether this potential improve-including the peritoneal cavity [26, 30–32]. In the present
ment in membrane status will have a long-term impact onstudy, however, there were no changes in either parame-
deleterious changes in membrane function awaits moreter with time in the B/L group or the C group. The
extended clinical experience and further planned con-observations on collagen turnover concur with the data
trolled trials. These observations appear to support theof Cappelli et al who did not observe significant changes
hypothesis that more biocompatible PD solutions willin their cross-over study (when measuring procollagen
reduce peritoneal inflammation and preserve peritonealIII C-terminal peptide levels) over an extended treat-
membrane integrity. Both of these actions will hopefullyment period [67]. In contrast, Simonsen et al observed
serve to extend successful therapy time on PD.increases in both PICP and PIIICP when patients used
the low GDP solution (abstract; Simonsen et al, ibid).
The reason for the difference between the results pre- NOTE ADDED IN PROOF
sented here and this latter study is unclear, however, the For further information, the reader is referred to the
lack of change (and possibly the apparent trend toward recently published article: Rippe B, Simonsen O, Heim-
a reduction observed in the B/L treatment groups after burger O, et al: Long-term clinical effects of a peritoneal
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